For 20 years Tim Heverin has represented clients in high-value patent and trade secret disputes, often involving international actors, activity, and witnesses. In doing so he has appeared before district courts across the country, the Federal Circuit, the ITC, and PTAB.
In particular Tim has extensive experience litigating life science patent disputes. He has represented clients in matters concerning pharmaceutical and biologic products such as Prezista®, Hytrin®, Tricor®, Istodax®, and Kuvan®. He recently was part of the team that successfully defeated an institution of four IPRs and defended a separate interference action related to formulation patents for top-selling drug, Humira®.
In addition to his pharmaceutical work Tim has handled patent disputes relating to medical devices, chemical processing, semiconductor fabrication and function, microchip architecture, information theory and coding, and search and database mining.
Tim serves as the Hiring Partner for the Chicago Office, where he heads the office's Recruiting Committee, and as co-chair of the Firm's IP Recruiting and Associate Development Committee. He also serves on the board of directors of the Lawyers' Committee for Better Housing.
Prior to attending law school Tim worked in the U.S. Naval Nuclear Propulsion Program as a nuclear plant engineer at Knolls Atomic Power Laboratory's Kesselring site, where, among other things, he instructed Naval officers in nuclear plant operation and casualty response.
- May 2018Additional Discovery: Must Be More Than Mere Possibility, PTAB Litigation Blog
- April 2018It’s Obvious: POSA Could Write Software To Generate Conference Call Requests, PTAB Litigation Blog
- December 2017Federal Circuit Rules BPCIA Preempts State Law
- June 2017Supreme Court: Biosimilar Applicants May Provide Commercial Marketing Notice Before FDA Approval
- July 2016180-Day Notice of Commercial Marketing Mandatory Even When Biosimilar Applicants Do the "Patent Dance"
- March 2016New Amgen Complaint Seeks Declaration Regarding Participation in the BPCIA's "Patent Dance"
- March 2016New BPCIA Complaint Alleges that Proposed Biosimilar Version of Enbrel® Infringes Five Patents
- December 2015Southern District of Florida Rules that 180-Day Notice of Commercial Marketing Is Mandatory When Parties "Patent Dance"
- University of Notre Dame (J.D. summa cum laude 1997; Articles Editor, Law Review; B.S.M.E. 1991)